Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
NCT05153330
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key points about the study:
- The treatment involves a combination of different medications that target the cancer cells in unique ways.
- It aims to enhance the effectiveness of existing therapies by using a multi-drug approach.
- Patients will receive close monitoring throughout the study to assess how well the treatment is working and to manage any side effects.
- This study is unique because it combines therapies that have not been used together before, potentially leading to better results.
- Participants will have the opportunity to contribute to research that could improve future treatments for others with the same condition.
Third Opinion AI Generated Synopsis
Trial Summary
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
